- Home
- TNGX vs ADTN Comparison
TNGX vs ADTN Comparison
Compare TNGX & ADTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- ADTN
- Stock Information
- Founded
- TNGX 2014
- ADTN 1985
- Country
- TNGX United States
- ADTN United States
- Employees
- TNGX N/A
- ADTN N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- ADTN Telecommunications Equipment
- Sector
- TNGX Health Care
- ADTN Telecommunications
- Exchange
- TNGX Nasdaq
- ADTN Nasdaq
- Market Cap
- TNGX 723.2M
- ADTN 738.9M
- IPO Year
- TNGX N/A
- ADTN 1994
- Fundamental
- Price
- TNGX $7.58
- ADTN $9.19
- Analyst Decision
- TNGX Strong Buy
- ADTN Strong Buy
- Analyst Count
- TNGX 6
- ADTN 5
- Target Price
- TNGX $10.00
- ADTN $12.80
- AVG Volume (30 Days)
- TNGX 2.6M
- ADTN 2.5M
- Earning Date
- TNGX 11-05-2025
- ADTN 11-05-2025
- Dividend Yield
- TNGX N/A
- ADTN N/A
- EPS Growth
- TNGX N/A
- ADTN N/A
- EPS
- TNGX N/A
- ADTN N/A
- Revenue
- TNGX $24,296,000.00
- ADTN $983,368,000.00
- Revenue This Year
- TNGX $20.42
- ADTN $17.80
- Revenue Next Year
- TNGX N/A
- ADTN $8.46
- P/E Ratio
- TNGX N/A
- ADTN N/A
- Revenue Growth
- TNGX N/A
- ADTN 3.52
- 52 Week Low
- TNGX $1.03
- ADTN $5.67
- 52 Week High
- TNGX $8.80
- ADTN $12.44
- Technical
- Relative Strength Index (RSI)
- TNGX 51.87
- ADTN 45.85
- Support Level
- TNGX $7.66
- ADTN $9.17
- Resistance Level
- TNGX $8.80
- ADTN $9.66
- Average True Range (ATR)
- TNGX 0.51
- ADTN 0.32
- MACD
- TNGX -0.04
- ADTN -0.06
- Stochastic Oscillator
- TNGX 33.70
- ADTN 49.15
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About ADTN ADTRAN Holdings Inc.
Adtran Holdings Inc is a provider of networking and communications platforms, software, and services focused on the broadband access market. It operates under two reportable segments: Network Solutions, which includes hardware and software products that enable a digital future that supports the company's Subscriber, Access & Aggregation, and Optical Networking Solutions; and Services & Support Segment which includes network design, implementation, maintenance and cloud-hosted services supporting the company's Subscriber, Access & Aggregation, and Optical Networking Solutions.